Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.61 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | HTR7 | P34969 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29950079 | 0.89 | KCNH2 (0.55) | HTR1AADRA1BKCNH2SIGMAR1HTR7 | |
| SCHEMBL29950038 | 0.79 | HTR1A (0.59) | HTR1AADRA1BHTR7 | |
| SCHEMBL30767216 | 0.74 | KCNH2 (0.90) | HTR1AKCNH2SIGMAR1HTR7 | |
| SCHEMBL32677386 | 0.74 | HTR1A (0.53) | HTR1AADRA1BKCNH2HTR7 | |
| SCHEMBL1254408 | 0.73 | KCNH2 (0.77) | HTR1AKCNH2SIGMAR1HTR7 | |
| Hydrochloric Acid SCHEMBL7658247 | 0.73 | KCNH2 (0.88) | HTR1AKCNH2SIGMAR1HTR7 | |
| SCHEMBL4525555 | 0.73 | KCNH2 (1.00) | HTR1AKCNH2SIGMAR1HTR7 | |
| SCHEMBL13711973 | 0.73 | KCNH2 (0.87) | KCNH2 | |
| SCHEMBL13711969 | 0.72 | KCNH2 (0.70) | HTR1AKCNH2SIGMAR1HTR7 | |
| SCHEMBL12654684 | 0.72 | DOCK5 (0.54) | HTR1AADRA1BSIGMAR1HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220306629-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | PRAEVENTIX, LLC | 2022-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306629-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | HTR7, HTR5A, HTR1A | HTR1A 3/4885ADRA1B 85/4885KCNH2 3278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.